MASLD in Primary Hypothyroidism and Efficacy of Dapaglifozin

Dapagliflozin 10mg daily will be given to the treatment arm.Eligible subjects will be followed up until week 28, and will undergo clinical, anthropometric and laboratory assessments (including liver function test and lipid profile) at baseline, week 14 and week 28. They will undergo LSM and CAP By Transient Elastography at baseline, week 14 and week 28, and MRI-PDFF at baseline and week 28. The primary outcome will be a difference in change of liver fat content (measured by MRI-PDFF) at week 28 from baseline between the two groups.

The placebo pills will be manufactured to be identical in appearance to the study drug(Dapaglifozin 10 mg tablet).

Levothyroxine Replacement daily for 28 weeka